The era of enforcement actions targeting large pharmaceutical companies’ off-label promotional practices may be coming to a close, but government lawyers are eyeing a new wave of industry practices for scrutiny and potential prosecution.
Among these are unsupported promotional claims of economic superiority and superior efficacy, manufacturers’ dealings with payers, misrepresentation of scientific studies,...